Estracyt Therapy of Advanced Prostatic Cancer with Special Reference to Control of Therapy with Cytology and DNA Cytophotometry

Abstract

Patients (81) with advanced prostate carcinoma, mainly estrogen resistant, were treated with Estracyt. After a pilot study showed encouraging results in the 1st 39 cases, the preparation was used on another 42 patients; for 38 of these its therapeutic effectiveness was evaluated according to internationally defined clinical criteria. An objective therapeutic success quota of 55% of all 38 patients was obtained. In the group with estrogen-resistant tumors the value was still as high as 35%. These clinical results were confirmed by cytomorphological control of the degree of regression of the tumor effected by the therapy and by single-cell cytophotometric analysis of the DNA content of various prostate carcinomas treated with Estracyt.